Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korean Government Accelerates Support For Homegrown Biosimilars

This article was originally published in PharmAsia News

Executive Summary

SEOUL - While South Korea's FDA is getting ready to release its initial version of registration guidelines for biosimilars, the Ministry for Knowledge Economy said it would use public funds to help local pharma and biotech companies to compete in the biosimilar arena

You may also be interested in...



Korean Government Announces Joint Fund To Beef Up Local Pharma Industry

SEOUL - The Korean government is moving to create a KRW2 trillion ($1.7 billion) research and development fund to help local Korean pharma companies develop globally competitive new drugs

Korean Government Announces Joint Fund To Beef Up Local Pharma Industry

SEOUL - The Korean government is moving to create a KRW2 trillion ($1.7 billion) research and development fund to help local Korean pharma companies develop globally competitive new drugs

Korea's Celltrion Signs Deal with Hungary's Egis Pharmaceuticals to Sell Biosimilars In Former Soviet Republic Countries, Eastern Europe

SEOUL - South Korea's Celltrion has signed a deal with Hungary's Egis Pharmaceuticals to sell Celltrion's future biosimilar products in the former Soviet Republic countries and Eastern Union

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC071853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel